Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
Main Authors: | Hammond, Flora M., Alexander, David N., Cutler, Andrew J., D’Amico, Stephen, Doody, Rachelle S., Sauve, William, Zorowitz, Richard D., Davis, Charles S., Shin, Paul, Ledon, Fred, Yonan, Charles, Formella, Andrea E., Siffert, Joao |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010732/ |
Similar Items
-
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
by: Hammond, Flora M., et al.
Published: (2016) -
Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect
by: Schoedel, Kerri A, et al.
Published: (2014) -
Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA®) for Pseudobulbar Affect
by: Pioro, Erik P.
Published: (2014) -
An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions
by: Pattee, Gary L., et al.
Published: (2014) -
Diagnosing pseudobulbar affect in traumatic brain injury
by: Engelman, William, et al.
Published: (2014)